Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
40

Summary

Conditions
  • Advanced Solid Cancer
  • Esophageal Cancer
  • Malignant (Pleural) Mesothelioma
  • Non -Small Cell Lung Cancer
  • Ovarian Cancer
Type
Interventional
Phase
Phase 1
Design
Allocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: Beginning with 150 mg dose level, and escalating to 300mg, 450mg, 600mg, 750mg, and 900mg dose level sequentially under "3+3" designMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 75 years
Gender
Both males and females

Description

Not Provided

Not Provided

Tracking Information

NCT #
NCT03917043
Collaborators
Suzhou Yasheng Pharmaceutical Co., Ltd.
Investigators
Principal Investigator: Li Zhang, Professor Sun Yat-sen University